Top

Published in:

17-01-2022 | Obesity | Original Article

Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study

Authors: Khaled Gaballa, Islam H. Metwally, Basel Refky, Shadi Awny, Mohamed Abdelkhalek, Mohamed Hamdy

Published in: Indian Journal of Surgical Oncology | Issue 3/2022

Abstract

Obesity has long been associated with endometrial cancer. However, there is a paucity of studies addressing the impact of morbid obesity in type II endometrial cancer on oncologic and surgical outcomes. In this study, the author retrospectively compared morbid to non-morbid obese in clinico-epidemiologic, surgical, and oncologic outcomes. Both groups were comparable as regards all clinico-epidemiologic parameters. Vaginal involvement, survival, and recurrence were also comparable between the 2 groups. Para-aortic adenopathy and treatment with preoperative therapy were the only significant predictors of DFS. Surgery is feasible with equivalent complications and oncologic outcomes in morbidly obese patients with type II endometrial cancer.

Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630):1134. https://doi.org/10.1136/bmj.39367.495995.AECrossRefPubMedPubMedCentral

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4(8):579–591. https://doi.org/10.1038/nrc1408CrossRefPubMed

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (London, England) 371(9612):569–578. https://doi.org/10.1016/S0140-6736(08)60269-XCrossRef

Fambrini M, Pieralli A, Bitossi U et al (2012) Mini-laparotomy versus vaginal surgery for class II-III obese patients with early-stage endometrial cancer. Anticancer Res 32(2):707–712PubMed

Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2007) Treatment modalities in endometrial cancer. Curr Opin Oncol 19(5):479–485. https://doi.org/10.1097/CCO.0b013e32827853c0CrossRefPubMed

Santi A, Kuhn A, Gyr T et al (2010) Laparoscopy or laparotomy? A comparison of 240 patients with early-stage endometrial cancer. Surg Endosc 24(4):939–943. https://doi.org/10.1007/s00464-009-0565-5CrossRefPubMed

Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol Off J Am Soc Clin Oncol 24(29):4783–4791. https://doi.org/10.1200/JCO.2006.06.7173CrossRef

Prat J, Gallardo A, Cuatrecasas M, Catasús L (2007) Endometrial carcinoma: pathology and genetics. Pathology 39(1):72–87. https://doi.org/10.1080/00313020601136153CrossRefPubMed

Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15(1):10–17. https://doi.org/10.1016/0090-8258(83)90111-7CrossRefPubMed

10.

Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6(2):93–108. https://doi.org/10.1097/00000478-198203000-00002CrossRefPubMed

11.

Fader AN, Nagel C, Axtell AE et al (2009) Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 112(3):558–562. https://doi.org/10.1016/j.ygyno.2008.11.016CrossRefPubMed

12.

Fader AN, Starks D, Gehrig PA et al (2009) An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 115(2):244–248. https://doi.org/10.1016/j.ygyno.2009.07.030CrossRefPubMed

13.

Zhang Y, Liu Z, Yu X et al (2010) The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol 117(1):41–46. https://doi.org/10.1016/j.ygyno.2009.12.029CrossRefPubMed

14.

Setiawan VW, Yang HP, Pike MC et al (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol Off J Am Soc Clin Oncol 31(20):2607–2618. https://doi.org/10.1200/JCO.2012.48.2596CrossRef

15.

McCullough ML, Patel AV, Patel R et al (2008) Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol biomarkers Prev a Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol 17(1):73–79. https://doi.org/10.1158/1055-9965.EPI-07-2567CrossRef

16.

Bjørge T, Engeland A, Tretli S, Weiderpass E (2007) Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J cancer 120(2):378–383. https://doi.org/10.1002/ijc.22260CrossRefPubMed

17.

Afshin A, Forouzanfar MH, Reitsma MB et al (2017) Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377(1):13–27. https://doi.org/10.1056/NEJMoa1614362CrossRefPubMed

18.

Pavelka JC, Ben-Shachar I, Fowler JM et al (2004) Morbid obesity and endometrial cancer: surgical, clinical, and pathologic outcomes in surgically managed patients. Gynecol Oncol 95(3):588–592. https://doi.org/10.1016/j.ygyno.2004.07.047CrossRefPubMed

19.

Giugale LE, Di Santo N, Smolkin ME, Havrilesky LJ, Modesitt SC (2012) Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia. Gynecol Oncol 127(2):326–331. https://doi.org/10.1016/j.ygyno.2012.08.014CrossRefPubMed

20.

Santoso JT, Barton G, Riedley-Malone S, Wan JY (2012) Obesity and perioperative outcomes in endometrial cancer surgery. Arch Gynecol Obstet 285(4):1139–1144. https://doi.org/10.1007/s00404-011-2116-2CrossRefPubMed

21.

Januszek SM, Barnas E, Skret-Magierlo J et al (2019) Obesity as a risk factor of in-hospital outcomes in patients with endometrial cancer treated with traditional surgical mode. Ginekol Pol 90(10):549–556. https://doi.org/10.5603/GP.2019.0095CrossRefPubMed

22.

Akbayır O, Corbacıoglu Esmer A, Numanoglu C et al (2012) Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer. Arch Gynecol Obstet 286(5):1269–1276. https://doi.org/10.1007/s00404-012-2431-2CrossRefPubMed

23.

Rabischong B, Larraín D, Canis M et al (2011) Long-term follow-up after laparoscopic management of endometrial cancer in the obese: a fifteen-year cohort study. J Minim Invasive Gynecol 18(5):589–596. https://doi.org/10.1016/j.jmig.2011.05.015CrossRefPubMed

24.

Erkanli S, Kayaselçuk F, Bagis T, Kuşçu E (2006) Impact of morbid obesity in surgical management of endometrial cancer: surgical morbidity, clinical and pathological aspects. Eur J Gynaecol Oncol 27(4):401–404PubMed

25.

Gambacorti-Passerini ZM, López-De la Manzanara Cano C, Pérez Parra C, et al. (2019) Obesity in patients with endometrial cancer: may it affect the surgical outcomes of laparoscopic approach? Obes Surg. 29(10):3285–3290. https://doi.org/10.1007/s11695-019-03986-2

26.

Watari H, Todo Y, Takeda M, Ebina Y, Yamamoto R, Sakuragi N (2005) Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol 96(3):651–657. https://doi.org/10.1016/j.ygyno.2004.11.026CrossRefPubMed

27.

Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS (1991) Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 78(1):63–69PubMed

28.

Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40(1):55–65. https://doi.org/10.1016/0090-8258(91)90086-kCrossRefPubMed

29.

Jeong N-H, Lee J-M, Lee J-K et al (2010) Role of body mass index as a risk and prognostic factor of endometrioid uterine cancer in Korean women. Gynecol Oncol 118(1):24–28. https://doi.org/10.1016/j.ygyno.2010.03.001CrossRefPubMed

30.

Modesitt SC, Tian C, Kryscio R et al (2007) Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol 105(1):59–65. https://doi.org/10.1016/j.ygyno.2006.10.045CrossRefPubMed

Title: Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study
Authors: Khaled Gaballa
Islam H. Metwally
Basel Refky
Shadi Awny
Mohamed Abdelkhalek
Mohamed Hamdy
Publication date: 17-01-2022
Publisher: Springer India
Keywords: Obesity
Obesity
Hysterectomy
Endometrial Cancer
Endometrial Cancer
Published in: Indian Journal of Surgical Oncology / Issue 3/2022
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-022-01503-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of Morbid Obesity on the Outcomes of Type II Endometrial Cancer: a Cohort Study

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Ex Situ In Vivo Technique of Spleen-Preserving Splenic Hilar Lymph Node Dissection in Operable Proximal Gastric Adenocarcinoma

Evaluation of Biochemical Recurrence and Correlation with Various Parameters After Robotic-Assisted Radical Prostatectomy: a Single Center Experience

Outcome of Postoperative Facial Nerve Function Following Electromyographic Facial Nerve Monitoring During Parotidectomy for Benign Lesions: a Retrospective Study

Tumor budding as a prognostic indicator in colorectal carcinoma: a retrospective study of primary colorectal carcinoma cases in a tertiary care center

Breast Cancer—Comprehensive Management

Efficiency of Blood Utilization in Elective Oncosurgeries in a Tertiary Care Cancer Centre: A Case for Data Disaggregation